Related Experiment Videos
Iotrol, a new water-soluble non-ionic dimeric contrast medium for intrathecal use
Neuroradiology
|January 1, 1985
Summary
Iotrol showed fewer side effects compared to metrizamide and iopamidol in intrathecal use. This study suggests Iotrol is the safest contrast agent for cerebrospinal fluid injections.
Area of Science:
- Neuroradiology
- Pharmacology
- Medical Imaging
Background:
- Intrathecal contrast agents are crucial for neuroradiological imaging.
- Assessing the safety and efficacy of new contrast agents is essential.
Purpose of the Study:
- To evaluate the side effect profile of Iotrol in comparison to metrizamide and iopamidol.
- To investigate the relationship between contrast medium distribution in the cerebrospinal fluid (CSF) space and headache occurrence.
- To assess the persistence of Iotrol in brain parenchyma using CT density profiles.
Main Methods:
- Two double-blind studies were conducted involving 100 patients.
- Side effects of Iotrol, metrizamide, and iopamidol were systematically recorded.
- CT density profiles were used to analyze contrast medium persistence in brain parenchyma.
Main Results:
- Iotrol demonstrated a favorable side effect profile compared to metrizamide and iopamidol.
- The distribution of contrast medium in the CSF space was analyzed for its correlation with headache.
- Iotrol exhibited lower persistence in the brain parenchyma than metrizamide and iopamidol.
Conclusions:
- Iotrol appears to be the safest contrast substance for intrathecal administration.
- Understanding contrast medium distribution is relevant for managing side effects like headache.